Male breast cancer develops when abnormal cells in the breast grow uncontrollably and form a malignant tumour. Although men have much less breast tissue than women, they still have breast ducts and can develop breast cancer.
Most male breast cancers begin in the ducts and are classified as invasive ductal carcinoma. Invasive lobular carcinoma is uncommon because the male breast normally contains few or no developed lobules. DCIS and other less common breast cancer types may also occur.
Most breast cancers in men are hormone receptor-positive. HER2-positive and triple-negative breast cancers can also develop, although they are less common. Treatment is based on the tumour's stage and biological features rather than the patient's sex alone.
Male breast cancer is sometimes diagnosed later because breast cancer may not be suspected when a man develops a breast lump or nipple change. Early evaluation of an unexplained breast abnormality is therefore important.
At Apollo Cancer Centres, male breast cancer care is planned by a multidisciplinary team that may include breast surgical oncologists, medical oncologists, radiation oncologists, radiologists, pathologists, genetic counsellors, reconstructive surgeons, and supportive-care professionals.
Risk Factors for Male Breast Cancer
Male Breast Cancer Signs and Symptoms
How Male Breast Cancer is Diagnosed
Diagnosis begins with a review of symptoms, medical history, previous radiation or hormone exposure, testicular and liver conditions, medication use, and family history. The doctor examines both breasts, nipples, underarms, and areas around the collarbones. Imaging is used to assess the abnormality, but a biopsy is required to confirm breast cancer.
Mammography
Diagnostic mammography is commonly used to assess a suspicious breast lump in an adult man. It may show:
A mass or asymmetrical density
Irregular or spiculated margins
Suspicious calcifications
Skin or nipple changes
More than one abnormal area
Features suggesting gynecomastia or another benign condition
Mammography can help distinguish a suspicious mass from typical gynecomastia, but it cannot confirm cancer without a biopsy.
Breast Ultrasound
Ultrasound uses sound waves to examine the breast and underarm. It may help:
Determine whether an abnormality is solid or fluid-filled
Assess the size and characteristics of a mass
Examine tissue behind the nipple
Evaluate suspicious lymph nodes
Guide a core needle biopsy
For younger men with an indeterminate breast lump, ultrasound may be performed before mammography. The imaging approach is determined by the patient's age, examination findings, and level of clinical concern.
Breast MRI
Breast MRI is not routinely required for every man with suspected breast cancer. It may be considered to:
Assess the extent of a confirmed cancer
Examine possible involvement of the nipple, skin, or chest wall
Look for additional abnormalities
Evaluate response to treatment given before surgery
Investigate uncertain findings on mammography or ultrasound
Examine the opposite breast in selected high-risk situations
MRI findings may require additional imaging or biopsy because benign abnormalities can also enhance.
CT Scan
A CT scan of the chest, abdomen, or pelvis may be performed when the cancer is locally advanced, symptoms suggest distant spread, or the findings would influence treatment. Routine CT staging is generally not required for every small, apparently localised breast cancer.
PET-CT
PET-CT may be considered for selected patients with:
Locally advanced breast cancer
Suspicious lymph nodes outside the usual regional areas
Possible metastatic disease
Uncertain abnormalities on other imaging
Recurrent breast cancer
PET-CT does not replace biopsy when tissue confirmation of an accessible abnormality is required.
Bone Scan
A bone scan may be used if symptoms, blood-test abnormalities, or the extent of disease raise concern about cancer spreading to the bones. PET-CT, CT, or MRI may be used instead in selected situations.
Core Needle Biopsy
Core needle biopsy is the preferred method for diagnosing most male breast cancers. A hollow needle removes several tissue samples from the abnormal area, usually under ultrasound guidance.
The tissue allows the pathologist to:
Confirm whether cancer is present
Determine whether it is invasive
Identify the histological type
Assess tumour grade
Test for ER, PR, and HER2
Perform additional biomarker tests when indicated
Lymph-Node Biopsy
A suspicious underarm or regional lymph node may undergo fine-needle aspiration or core needle biopsy. Confirmation of lymph-node involvement can affect staging and determine whether systemic treatment should be given before surgery.
Surgical Biopsy
An incisional or excisional biopsy may occasionally be required when a needle biopsy is not possible or does not provide a conclusive diagnosis. Most suspicious male breast masses can be diagnosed using a core needle biopsy.
Laboratory
The biopsy tissue is examined by a specialist breast pathologist. Assessment may include:
Histopathology: Identifies whether the tumour is invasive ductal carcinoma, DCIS, or another breast cancer type.
Tumour grading: Assesses tubule formation, nuclear appearance, and mitotic activity to determine how abnormal and active the cancer cells appear.
Estrogen receptor testing: Determines whether estrogen may stimulate tumour growth and whether endocrine therapy may be beneficial.
Progesterone receptor testing: Provides additional information about hormone-receptor status and likely sensitivity to endocrine treatment.
HER2 testing: Uses immunohistochemistry and, when required, in-situ hybridisation to determine whether the cancer is HER2-positive.
Ki-67 assessment: May be performed in selected cases to estimate the proportion of actively dividing tumour cells.
Lymphovascular invasion: Determines whether cancer cells are present within small lymphatic or blood vessels near the tumour.
Margin assessment: Establishes whether invasive cancer or DCIS reaches the edge of the surgically removed tissue.
Lymph-node assessment: Determines the number of sampled lymph nodes and whether they contain cancer.
Treatment-response assessment: After preoperative systemic therapy, determines how much invasive cancer remains in the breast and regional lymph nodes.
Genomic assays: May be considered for selected hormone receptor-positive, HER2-negative early breast cancers when the result could help determine the likely benefit of chemotherapy. Evidence in men is less extensive, and results must be interpreted in the complete clinical context.
Germline genetic testing: Looks for inherited cancer-associated variants. Genetic testing should be offered or strongly considered for men diagnosed with breast cancer because the result may affect treatment, future cancer surveillance, and risk assessment for biological relatives.
Genetic testing may include BRCA1, BRCA2, PALB2, CHEK2, ATM, TP53, PTEN, and other genes selected according to the personal and family history. A pathogenic BRCA2 variant is particularly associated with male breast cancer and may also increase the risk of prostate, pancreatic, and other cancers.
Blood tests may include a complete blood count, kidney and liver function tests, blood chemistry, and other assessments needed before treatment. Blood tumour markers cannot diagnose early male breast cancer and are not used for routine screening.
Male breast cancer is staged using the same TNM and prognostic staging principles applied to breast cancer in women. The clinical stage is determined before definitive surgery using examination, imaging, and biopsy results. The pathological stage is determined after surgery by examining the removed breast tissue and lymph nodes.
Stage I: The cancer is small and confined to the breast or associated with only minimal regional lymph-node involvement.
Stage II: The cancer is larger or has spread to a limited number of nearby lymph nodes.
Stage III: The cancer involves more regional lymph nodes, the breast skin, or the chest wall without confirmed distant spread.
Stage IV: The cancer has spread to distant organs such as the bones, liver, lungs, brain, or distant lymph nodes.
When systemic treatment is given before surgery, the post-treatment stage describes the amount of cancer remaining in the breast and lymph nodes.
Stage alone does not determine treatment. Hormone-receptor status, HER2 status, tumour grade, genetic findings, response to preoperative therapy, age, general health, and patient preference are also considered.
How Male Breast Cancer is Treated
Mastectomy
Mastectomy removes most or all breast tissue and is the most frequently performed operation for male breast cancer. It is commonly used because male breast tissue is limited and tumours often develop close to the nipple.
The operation may require removal of:
Breast tissue
The nipple and areola
Skin directly involved by the tumour
Tissue overlying the chest muscle
Part of the chest-wall muscle in uncommon cases of direct invasion
Breast-Conserving Surgery
Breast-conserving surgery removes the tumour with a rim of surrounding tissue while preserving the remaining breast.
It may be considered when:
The tumour is small relative to the available breast tissue
Clear surgical margins can be achieved
The nipple or extensive skin is not involved
An acceptable cosmetic result is possible
The patient can receive postoperative radiation therapy
Breast-conserving surgery is generally followed by radiation therapy. It is not unsuitable simply because the patient is male.
Sentinel Lymph-Node Biopsy
Sentinel lymph-node biopsy removes the first node or nodes most likely to receive drainage from the breast. It is commonly performed when the underarm lymph nodes do not appear to contain cancer. The procedure helps stage the cancer while limiting the extent of underarm surgery.
Axillary Lymph-Node Dissection
Axillary lymph-node dissection removes more lymph nodes from the underarm. It may be required when:
Several sentinel nodes contain cancer
Lymph-node involvement is confirmed before surgery
Significant nodal disease remains after preoperative treatment
Sentinel-node biopsy is unsuitable or unsuccessful
In selected cases, axillary radiation or more limited surgery may provide regional control while reducing the risk of lymphoedema, numbness, pain, and shoulder stiffness.
Endocrine Therapy
Most male breast cancers are estrogen receptor-positive. Tamoxifen is generally the preferred endocrine treatment for hormone receptor-positive breast cancer in men.
Tamoxifen may be recommended:
After surgery to reduce the risk of recurrence
Before surgery in selected patients
For locally advanced breast cancer
For recurrent or metastatic disease
Potential side effects include hot flushes, reduced sexual function, mood changes, weight change, fatigue, and blood clots. Side effects should be addressed actively because they can affect treatment adherence.
Aromatase Inhibitors
Aromatase inhibitors such as anastrozole, letrozole, or exemestane reduce estrogen production outside the testes. When used in men, they are generally combined with a gonadotropin-releasing hormone agonist or antagonist to suppress testicular hormone production. An aromatase inhibitor alone may not suppress estrogen adequately in men and is not routinely preferred over tamoxifen.
Other Endocrine and Targeted Treatment
For advanced hormone receptor-positive, HER2-negative breast cancer, treatment options may include:
Fulvestrant
CDK4/6 inhibitors
PI3K, AKT, or mTOR pathway inhibitors for appropriately selected tumours
Other endocrine-based combinations
The choice depends on previous treatment, genomic findings, disease extent, symptoms, and available approvals.
Chemotherapy
Chemotherapy may be recommended when:
The tumour has high-risk pathological features
Regional lymph nodes are involved
The cancer is hormone receptor-negative
The tumour is HER2-positive and chemotherapy is being combined with HER2-targeted therapy
The cancer is locally advanced
The cancer has spread or is progressing rapidly
Endocrine therapy is unlikely to provide adequate control
Chemotherapy may be given before surgery, after surgery, or for metastatic disease. The choice of regimen follows the same general principles used for breast cancer in women and is adjusted for age, cardiac health, kidney and liver function, previous treatment, and other medical conditions.
HER2-Targeted Therapy
HER2-positive male breast cancer is treated using HER2-directed approaches similar to those used for women.
Medicines may include:
Trastuzumab
Pertuzumab
Trastuzumab emtansine
Trastuzumab deruxtecan
Tucatinib
The choice depends on the stage, previous treatment, response to therapy, brain involvement, regulatory approval, and medicine availability. Cardiac function is assessed before and during selected HER2-targeted treatments.
PARP Inhibitors
A PARP inhibitor may be considered for an appropriately selected patient with a germline BRCA1 or BRCA2 pathogenic variant and HER2-negative breast cancer. Its use depends on whether the disease is early-stage or metastatic, previous treatment, regulatory approval, and current treatment guidelines.
Immunotherapy
Immunotherapy may be considered for selected patients with triple-negative metastatic breast cancer when the tumour meets the relevant biomarker criteria. It may also be used in certain high-risk early triple-negative cancers according to the treatment setting. Immune-checkpoint inhibitors are not routinely used for hormone receptor-positive breast cancer without another relevant indication.
Treatment of Metastatic Disease
Metastatic male breast cancer is generally managed using the same biological principles applied to metastatic breast cancer in women.
Treatment selection considers:
ER and PR status
HER2 status
Germline and tumour genetic findings
Previous treatment
Sites and extent of metastases
Symptoms and pace of progression
General health and organ function
Patient preferences and quality of life
Radiation After Breast-Conserving Surgery
Radiation therapy is generally recommended after breast-conserving surgery. It treats remaining breast tissue and reduces the risk of local recurrence. A focused additional dose may be delivered to the area where the tumour was removed.
Radiation After Mastectomy
Chest-wall radiation may be recommended when the risk of local recurrence is increased. Factors may include:
A large tumour
Skin, nipple, or chest-wall involvement
Positive or close surgical margins
Significant lymph-node involvement
Residual disease after preoperative treatment
Regional Nodal Radiation Therapy
Radiation may be directed to lymph-node regions near the breast when regional recurrence risk is increased. These may include the axillary, supraclavicular, or internal mammary lymph nodes.
Radiation for Advanced Disease
Radiation therapy may be used to:
Relieve pain from bone metastases
Treat or prevent spinal-cord compression
Control brain metastases
Reduce bleeding, ulceration, or pressure
Treat a symptomatic local recurrence
Control selected limited metastatic sites
Advanced techniques may include intensity-modulated radiation therapy, image-guided radiation therapy, stereotactic radiosurgery, or stereotactic body radiation therapy.
Chest-Wall Reconstruction
Most men do not require formal breast reconstruction after mastectomy. The operation is generally planned to produce a smooth chest contour and permit comfortable movement. Plastic or reconstructive surgery may be required when removal of a large tumour leaves a substantial skin or soft-tissue defect.
Nipple-Areola Reconstruction
Selected patients may consider nipple-areola reconstruction or medical tattooing after treatment. Suitability depends on the original tumour location, the surgery performed, radiation therapy, and personal preference.
Fat Grafting or Contour Correction
Fat grafting or scar revision may be considered after treatment to improve a chest-wall indentation, asymmetry, or contour irregularity. Any corrective procedure should be planned after confirming that cancer treatment is complete and the surgical area has healed.
The prognosis depends mainly on the stage and biological characteristics of the cancer. When compared at the same stage and with similar tumour features, treatment principles and outcomes can be broadly comparable to those for breast cancer in women.
Male breast cancer is sometimes diagnosed at a more advanced stage because early breast changes may be overlooked or attributed to a benign condition.
Regular follow-up is important because breast cancer can recur locally, regionally, or in distant organs. Follow-up may include clinical assessment, imaging of any remaining breast tissue, evaluation of treatment-related effects, and surveillance associated with an inherited genetic variant.
Why Choose ACC for Male Breast Cancer Treatment